- About Us
- Cell Therapy
- Animal Medicine
- Products & Services
- IR/PR
- Contact Us
Immune Cell Therapy
Immune Cell Therapy
Injection of in vitro cultured immune cells such as autologous or allogenic peripheral blood-derived dendritic cells, T cells, or natural killer cells (NK cells)
Cell therapy refers to the pharmaceuticals made from human or animal cells that have been manipulated and manufactured in vitro such as culturing, proliferation, and selection using physical, chemical, or biological methods (Advanced Regenerative Medicine and Advanced Therapy Medicinal Products Safety and Support Act, Legislation No.16556). Immune cell therapies are ATMPs that use immune cells such as dendritic cells, T cells, or natural killer cells to control or activate in vivo immune reactions to treat cancer, infective diseases, and autoimmune diseases.
Advantages of Immune Cell Therapy
Immune cell therapies are representative patient-tailored pharmaceuticals that are produced by manipulating and culturing cells taken from the patient to achieve desired characteristics such as immune enhancement or tolerance, which are then reintroduced into the patient’s body. The advantages of this treatment include lower toxicity and higher safety, and it is known to show excellent effects in patients with metastatic cancer. Also, when used in combination with conventional surgery, chemotherapy, and radiologic therapy, treatment and preventive effects are enhanced and adverse events are decreased to efficiently increase the quality of life of the patient.
Immune Cell Therapies, The Core Theme of the Next-Generation Bio Industry
Immune cell therapies currently in the market or under clinical research worldwide include dendritic cell therapies for hepatocellular carcinoma (CreaVax-HCC, JW CreaGene), activated T lymphocyte therapies for liver cancer (ImmuneCell-LC, Green Cross Cell), and dendritic cell therapies for prostatic cancer (Provenge, Dendreon), and hundreds of clinical trials are ongoing worldwide (www.clinicaltrials.gov). Immune cell therapy is actively being researched domestically and globally, and this ATMP is valued as the core theme of the next-generation bio industry.
Pharos Vaccine is actively taking on challenges in the fields of anti-cancer drugs and autoimmune disease treatment based on wide experience and competitive expertise in the establishment and manufacturing of cell therapy technologies such as cell separation, sensitization, culture, amplification, and genetic manipulation, as well as quality control, clinical trials, and approval with a view of development of innovative immune cell therapies.
Blood Collection
Cell Isolation &
Activation
Transduction &
Expansion
Cell Harvest &
Formulation
Quality Control
Infusion
